We further hypothesized that interruption of this signaling axis with EGFR or NF-κB inhibitors of silencing of ProT or HOTAIR would ameliorate cisplatin-induced bladder cancer cachexia. Here, NFKB1 is linked to urinary bladder carcinoma.